红蓝光联合维胺脂治疗中重度痤疮115例临床的应用效果及安全性的探讨.docVIP

红蓝光联合维胺脂治疗中重度痤疮115例临床的应用效果及安全性的探讨 　　[摘要] 目的 观察红蓝光联合维胺脂治疗中重度痤疮115例临床应用效果及安全性，探讨其临床适用性。 方法 选择自2013年1月～2014年6月于我院治疗的中重度痤疮患者330例，随机分为试验组和对照组各115例。观察并记录两组患者的临床疗效；对两组患者治疗前后进行GAGS评分；统计两组患者治疗前后皮疹改善情况；记录两组患者并发症发生情况。 结果 试验组和对照组的有效率分别为85.2%和61.7%，差异具有统计学意义（P0.05）。 结论 红蓝光联合维胺脂治疗中重度痤疮临床效果显著，安全性高，适合临床长期推广应用。 　　[关键词] 红蓝光；维胺脂；中重度痤疮；安全性 　　[中图分类号] R758.733 [文献标识码] B [文章编号] 2095-0616（2016）01-68-04 　　[Abstract] Objective To observe clinical applicative effect and safety of red and blue light combined with viaminate in treatment of severe acne in 115 cases and to explore its clinical applicability. Methods 330 patients with moderate to severe acne who were treated in our hospital from January 2013 to June 2014 were selected and they were randomly divided into the experimental group and control group， with 115 in each. Clinical curative effect of patients in two groups were observed and recorded. And they were received GAGS scoring before and after treatment. In addition， improvement of rash before and after treatment and occurrence of complication of patients in two groups were recorded. Results Effective rates of the experimental group and the control group were 85.2% and 61.7% respectively， and the difference was statistically significant （P0.05）. Conclusion Red and blue light combined with viaminate in treatment of moderate to severe acne has significant clinical effect and high safety， worthy of clinical long-term promotion and application. 　　[Key words] Red and blue light； Viaminate； Moderate to severe acne； Safety 　　痤疮乃因皮脂腺分泌过剩引起的一种慢性、炎症性皮肤疾患，在青春期多见，且发病率日趋增长[1]。本病是一种多因性疾病，容易复发，且病情轻重波动不定[2]。由于影响本病的因素很多，单一的药物治疗往往较难取得预期的效果，因此需要根据病情轻重程度采取综合性治疗[3]。我院通过将红蓝光照射与维胺脂联合治疗中重度痤疮，旨在探讨其临床应用效果及安全性，为临床提供可靠依据，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　病例选择标准：选择自2013年1月～2014年6月于我院治疗的中重度痤疮患者300例，入选患者均签署知情同意书，该研究获得院伦理委员会的批准，随机分为试验组和对照组各115例。试验组：男64例，女51例；年龄18～38岁，平均（22.4±4.7）岁；病程1～15个月，平均（4.7±3.6）个月；发病部位：面部48例、颈部25、背部36例、臀部6例。对照组：男67例，女48例，年龄19～39岁，平均（23.1±4.8）岁；病程1～17个月，平均（5.1±3.4）个月；发病部位：面部46例、颈部27、背部3